Holdings
Saturn V Capital Management LP
As of Jun 30, 2026, Saturn V Capital Management LP reported 20 positions worth US$604M. Largest: Amylyx Pharmaceuticals, Inc., Alumis Inc. and Abivax Sa. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. | 4.62M | US$83M | +274K | Jun 30, 2026 |
| Alumis Inc. | 2.92M | US$82M | −287K | Jun 30, 2026 |
| Abivax Sa | 519K | US$69.1M | −23,831 | Jun 30, 2026 |
| Vaxcyte, Inc. | 853K | US$49.6M | +28,382 | Jun 30, 2026 |
| Immix Biopharma, Inc. | 4.66M | US$48M | +965K | Jun 30, 2026 |
| Celcuity Inc. | 370K | US$38.7M | +88,414 | Jun 30, 2026 |
| Disc Medicine, Inc. | 525K | US$38.4M | +74,804 | Jun 30, 2026 |
| Candel Therapeutics, Inc. | 3.3M | US$34M | +407K | Jun 30, 2026 |
| X4 Pharmaceuticals, Inc. | 6.97M | US$32.6M | +517K | Jun 30, 2026 |
| Monopar Therapeutics Inc. | 312K | US$28.9M | −33,650 | Jun 30, 2026 |